Open AccessCariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
Author(s) -
José Manuel García Montes,
Paloma Juncosa Montes,
Daniel Hernández-Huerta
Publication year - 2021
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s298005
Subject(s) - medicine , schizophrenia (object oriented programming) , tolerability , partial agonist , exacerbation , antipsychotic , psychiatry , adverse effect , receptor , agonist
There are still some unmet needs in the treatment of schizophrenia like the persistence of negative symptoms. Cariprazine is a new-generation antipsychotic with partial agonism of the dopamine receptors, distinct from other antipsychotics by its 10 times greater affinity for D3 receptors. This mechanism of action could be especially favorable on patients with predominant negative symptoms. This report is showing three clinical cases of acute schizophrenia exacerbation that required hospitalization and were successfully treated with cariprazine. All of them had predominant positive symptoms and two of them had substance use. Efficacy of cariprazine was also crucial on negative and cognitive symptoms with excellent tolerability.